title: MET as a possible target for non-small-cell lung cancer.
abstract: Lung cancer is a heterogeneous group of disorders that is now being subdivided into molecular subtypes with dedicated targeted therapies. The MET receptor tyrosine kinase has been identified as aberrantly overexpressed, potentially having activating mutations, and amplified in certain subsets of lung cancers. The ligand hepatocyte growth factor (HGF) can also be overexpressed in lung cancer or expressed in stroma, and both the MET receptor and the HGF ligand can be targets for therapeutics, especially in lung cancer. Activation of MET leads to a plethora of biochemical and biologic changes both in normal and cancerous cells. Preclinically, it has been shown that silencing or inactivating MET leads to decreased viability of cancer cells. There are a number of compounds against MET/HGF in clinical trials that have been shown to be active in lung cancers. This review will summarize the biology of MET as well as its therapeutic inhibition in lung cancer.
authors: University of Chicago, Chicago, IL, USA.
authors: Ahad A
authors: AA
authors: Sadiq
authors: Ravi
authors: R
authors: Salgia
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D015972:Gene Expression Regulation, Neoplastic; D017228:Hepatocyte Growth Factor / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D009154:Mutation; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D017228:Hepatocyte Growth Factor; D019859:Proto-Oncogene Proteins c-met
references: Cancer Discov. 2011 Dec;1(7):573-9
references: 22389872
references: J Thorac Oncol. 2010 May;5(5):591-6
references: 20150826
references: J Thorac Oncol. 2008 Apr;3(4):331-9
references: 18379349
references: Exp Cell Res. 1986 Sep;166(1):139-50
references: 3527727
references: Cancer Res. 2008 Jun 1;68(11):4360-8
references: 18519697
references: Mol Cancer Ther. 2010 Jun;9(6):1544-53
references: 20484018
references: J Clin Oncol. 2015 Aug 20;33(24):2667-74
references: 26169611
references: N Engl J Med. 2009 Sep 3;361(10):947-57
references: 19692680
references: Oncogene. 2002 Jul 25;21(32):4885-93
references: 12118367
references: Cancer. 2009 May 15;115(10 Suppl):2252-61
references: 19402075
references: Cancer Res. 2005 Feb 15;65(4):1479-88
references: 15735036
references: Mol Cancer Ther. 2011 Dec;10(12):2298-308
references: 21926191
references: Cancer Cell. 2004 Jul;6(1):75-84
references: 15261143
references: Science. 2002 Jul 5;297(5578):102-4
references: 12098700
references: J Thorac Oncol. 2011 Oct;6(10):1624-31
references: 21716144
references: Clin Cancer Res. 2010 May 1;16(9):2677-87
references: 20406832
references: J Cell Sci. 1998 Jan;111 ( Pt 2):237-47
references: 9405310
references: Oncogene. 1994 Jun;9(6):1691-7
references: 8183564
references: J Clin Oncol. 2012 Mar 10;30(8):863-70
references: 22215748
references: Am J Physiol. 1995 Jun;268(6 Pt 2):F1211-7
references: 7611461
references: J Clin Oncol. 2012 Jan 20;30(3):e30-3
references: 22162573
references: J Carcinog. 2008;7:9
references: 19240370
references: PLoS One. 2012;7(2):e31906
references: 22363766
references: Nat Rev Cancer. 2010 Nov;10(11):760-74
references: 20966921
references: Cancer Res. 2007 May 1;67(9):4408-17
references: 17483355
references: EMBO J. 2004 Jun 16;23(12):2325-35
references: 15167892
references: Clin Cancer Res. 2010 Jul 1;16(13):3507-16
references: 20472683
references: Lab Invest. 2009 Mar;89(3):301-14
references: 19139719
references: Nature. 1999 Jul 29;400(6743):468-72
references: 10440378
references: Cancer Res. 2003 Nov 1;63(21):7345-55
references: 14612533
references: Clin Pharmacol Drug Dev. 2018 Jun;7(5):532-542
references: 29346833
references: J Thorac Oncol. 2011 May;6(5):942-6
references: 21623265
references: Br J Cancer. 2007 Aug 6;97(3):368-77
references: 17667909
references: Nat Clin Pract Oncol. 2006 Aug;3(8):448-57
references: 16894390
references: Lancet Oncol. 2011 Aug;12(8):735-42
references: 21783417
references: Br J Cancer. 1996 Dec;74(12):1862-8
references: 8980383
references: Cell. 2002 May 3;109(3):321-34
references: 12015982
references: J Cell Biol. 1993 Oct;123(1):223-35
references: 8408200
references: Curr Opin Mol Ther. 2009 Aug;11(4):448-55
references: 19649990
references: Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
references: 18093943
references: Jpn J Cancer Res. 1996 Oct;87(10):1063-9
references: 8957065
references: Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6735-42
references: 18006775
references: Cancer Res. 2003 Oct 1;63(19):6272-81
references: 14559814
references: Cancer Cell. 2003 Apr;3(4):347-61
references: 12726861
references: Genet Test. 2001 Summer;5(2):101-6
references: 11551094
references: Nat Genet. 2000 Jan;24(1):57-60
references: 10615128
references: J Med Chem. 2011 Sep 22;54(18):6342-63
references: 21812414
references: Neoplasia. 2000 May-Jun;2(3):226-34
references: 10935508
references: PLoS One. 2010 Jan 29;5(1):e8972
references: 20126411
references: Cancer Res. 2005 Mar 15;65(6):2412-21
references: 15781657
references: Cancer Res. 2006 May 1;66(9):4750-7
references: 16651428
references: J Biol Chem. 2011 Jun 10;286(23):20666-76
references: 21454604
references: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144-52
references: 17062691
references: Nature. 2007 Aug 2;448(7153):561-6
references: 17625570
references: Cancer Res. 2007 Mar 1;67(5):2081-8
references: 17332337
references: Oncogene. 1994 Jul;9(7):2019-27
references: 8208547
references: Cancer Cell. 2004 Jul;6(1):61-73
references: 15261142
references: Science. 2007 May 18;316(5827):1039-43
references: 17463250
references: Mol Cell. 1999 Aug;4(2):199-207
references: 10488335
references: Lancet Oncol. 2011 Oct;12(11):1004-12
references: 21933749
references: Cancer Res. 1997 Feb 1;57(3):433-9
references: 9012470
references: J Thorac Oncol. 2009 Jan;4(1):5-11
references: 19096300
references: Nature. 1984 Sep 6-11;311(5981):29-33
references: 6590967
references: Mol Cancer Ther. 2010 Feb;9(2):400-9
references: 20124448
references: Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4046-51
references: 16537482
references: FEBS Lett. 1987 Nov 30;224(2):311-6
references: 3319692
references: Cancer Res. 2002 Sep 15;62(18):5126-8
references: 12234972
references: Mol Cancer Ther. 2003 Nov;2(11):1085-92
references: 14617781